Unlocking the potential of
genomic medicine

2018 News Releases

Date Title
Toggle Summary12/04/2017
PHILADELPHIA , Dec. 4, 2017 /PRNewswire/ -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced today the appointment of Matthew D. Bayley , MD, MBA to its Board of Directors. "We are excited to welcome Matt to our Board of Directors during this important time for the Company," said
Toggle Summary11/02/2017
PHILADELPHIA , Nov. 2, 2017 /PRNewswire/ --  Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced today financial and operational results for the quarter ended September 30, 2017 and provided a corporate update. Third Quarter and Recent Corporate Highlights Initiated screening and
Toggle Summary10/17/2017
PHILADELPHIA , Oct. 17, 2017 /PRNewswire/ --  Aevi Genomic Medicine, Inc. (NASDAQ: GNMX)(the " Company ") today announced the completion of a previously announced private placement of 22.2 million shares of its common stock with warrants to purchase approximately 4.0 million additional shares of
Toggle Summary09/05/2017
PHILADELPHIA , Sept. 5, 2017 /PRNewswire/ --  Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced today that Michael F. Cola , President and Chief Executive Officer, will be presenting at the Rodman & Renshaw 19th Annual Global Investment at 2:35 PM EDT in New York, NY on Monday,
Toggle Summary08/10/2017
PHILADELPHIA , Aug. 10, 2017 /PRNewswire/ -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the "Company") today announced the execution of a definitive agreement to sell shares of common stock and warrants to purchase common stock in a private placement, or PIPE, to certain accredited investors, led
Toggle Summary08/09/2017
PHILADELPHIA , Aug. 9, 2017 /PRNewswire/ --  Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced today financial and operational results for the quarter ended June 30, 2017 and provided a corporate update. Second Quarter Corporate Highlights Initiating Phase 2 clinical trial in
Toggle Summary06/13/2017
PHILADELPHIA , June 13, 2017 /PRNewswire/ -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced today that Michael F. Cola , President and Chief Executive Officer, will be a participant on the Emerging Landscape of Orphan / CNS Disorders Panel at the JMP Securities Life Sciences
Toggle Summary05/10/2017
PHILADELPHIA, PA -- (Marketwired) -- 05/10/17 -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) Company to initiate a Phase 2 clinical trial in 2H 2017, targeting a specific genetic subset of patients identified by a responder analysis of the SAGA trial Responder subset is approximately 10% of the US
Toggle Summary05/03/2017
PHILADELPHIA, PA -- (Marketwired) -- 05/03/17 -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced today it will host a conference call and live audio webcast on Wednesday, May 10, 2017 at 8:30 a.m. EDT to report financial results for the first quarter and discuss recent business
Toggle Summary04/27/2017
PHILADELPHIA, PA -- (Marketwired) -- 04/27/17 -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced today that Michael F. Cola , President and Chief Executive Officer, will present at the 42nd Annual Deutsche Bank Health Care Conference on Thursday, May 4, 2017 at 1:10 p.m.